# CAMPO Administrative and Coordinating Core

> **NIH NIH U54** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $239,261

## Abstract

ABSTRACT FOR ADMINISTRATIVE AND COORDINATING CORE
The California-Mexico-Puerto Rico (CAMPO) Consortium will perform three clinical research studies 
focused on the prevention of cervical cancer among HIV-positive women in Mexico and Puerto Rico. Study 1 
will examine new screening algorithms for cervical high-grade squamous intraepithelial lesions (HSIL) in 4000 
HIV-positive women in Mexico and Puerto Rico. Study 2 will evaluate the impact of anogenital probiotic use on 
anal and cervical microbiota profiles and the relationship to anal and cervical HSIL regression in 600 HIV-positive women and men as well as reduction of high-risk HPV DNA persistence among those with no lesions. 
Study 3 will evaluate the safety and efficacy of a multivalent replication-defective adenovirus-based 
therapeutic HPV vaccine to treat cervical and anal HSIL in 300 HIV-positive women and men and identify 
immune response correlates of HSIL regression. The CAMPO Consortium will be overseen by the 
Administrative and Coordinating Core (ACC). Working with the Data Management and Statistics Core, Central 
Laboratory Core and the Clinical Trials Program, the ACC has the following aims: (1) To facilitate effective, 
regular and sustainable means of communication between Consortium members and Consortium activities; (2) 
To provide necessary infrastructure, regulatory, and operational support for the Clinical Trials Program; (3) To 
support career development and research infrastructure for early career investigators with research interests in 
HIV and HPV-related malignancies in Latin America; (4) To monitor and evaluate the impact of the Consortium; 
and (5) To ensure the identification, continuous participation, and bi-directional integration of NIH officials, the 
External Scientific Advisory Group (ESAG) and Community Advisory Board (CAB) and policymakers in the 
Consortium’s activities. The ACC will be led by UCSF Contact MPI Dr. Joel Palefsky, and co-led by MPIs Dr. 
Ana Ortiz Martinez of UPR and Dr. Jorge Salmeron of INSP. The other members of the ACC will include the 
major stakeholders in the Consortium, including the chair of the Steering Committee, the leader of the Clinical 
Trials Program, the chair of the Community Advisory Board, and a representative of The Emmes Corporation. 
The ACC will meet biweekly to discuss Consortium activities, monitor progress, and ensure that all 
components of the Consortium are working together effectively. The ACC will provide guidance to the 
Executive Committee, which is comprised of the three Principal Investigators and will serve as the decision-making body for the Consortium.

## Key facts

- **NIH application ID:** 11177200
- **Project number:** 5U54CA242646-06
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** JOEL Michael PALEFSKY
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $239,261
- **Award type:** 5
- **Project period:** 2019-09-12 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11177200

## Citation

> US National Institutes of Health, RePORTER application 11177200, CAMPO Administrative and Coordinating Core (5U54CA242646-06). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11177200. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*